The Prognostic Value of Systemic Inflammatory Markers in Advanced Renal Cell Carcinoma Patients Treated With Molecular Targeted Therapies

The present study examined the impact of systemic inflammatory markers including C-reactive protein (CRP)/Albumin (Alb) and neutrophil lymphocyte ratio (NLR)/Alb on the prognosis of patients treated with first line molecular targeted therapy for advanced RCC. A total of 131 patients with advanced RC...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2020-03, Vol.40 (3), p.1739-1745
Main Authors: Ueda, Kosuke, Ogasawara, Naoyuki, Yonekura, Satoru, Matsunaga, Yoshihiro, Hoshino, Ryuji, Kurose, Hirofumi, Chikui, Katsuaki, Uemura, Keiichiro, Nakiri, Makoto, Nishihara, Kiyoaki, Matsuo, Mitsunori, Suekane, Shigetaka, Igawa, Tsukasa
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Albumins
Biomarkers
Biomarkers, Tumor - metabolism
C-reactive protein
Carcinoma, Renal Cell - mortality
Carcinoma, Renal Cell - pathology
Carcinoma, Renal Cell - therapy
Female
Humans
Inflammation
Kidney cancer
Lymphocytes
Male
Medical prognosis
Middle Aged
Molecular Targeted Therapy - methods
Nephrectomy
Prognosis
Renal cell carcinoma
Retrospective Studies
Survival
Survival Rate
Therapy
Young Adult
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The present study examined the impact of systemic inflammatory markers including C-reactive protein (CRP)/Albumin (Alb) and neutrophil lymphocyte ratio (NLR)/Alb on the prognosis of patients treated with first line molecular targeted therapy for advanced RCC. A total of 131 patients with advanced RCC treated with molecular targeted therapy as first line treatment from May 2008 to April 2019 were retrospectively analyzed. High CRP, high NLR, low Alb and high CRP/Alb showed significantly worse progression-free survival (PFS) and overall survival (OS) than low CRP, low NLR, high Alb, low CRP/Alb and low NLR/Alb, respectively. In multivariate analyses, prior nephrectomy (p=0.0321) and NLR/Alb ratio (p=0.0327) were independent prognostic factors for PFS. Furthermore, prior nephrectomy (p=0.0013) and CRP/Alb ratio (p=0.0020) were independent prognostic factors for OS. CRP/Alb and NLR/Alb ratios are useful and independent prognostic biomarkers in patients with advanced RCC treated with molecular targeted therapy.
ISSN:0250-7005
1791-7530
DOI:10.21873/anticanres.14127